INTRODUCTION
============

Urinary tract stones are one of the most prevalent urological disorders. It has been estimated that up to 12% of the population will suffer from urinary stones during their lifetime, and recurrence rates approach 50% \[[@B1]\]. Several treatment methods exist, including observation (awaiting spontaneous passage), shock wave lithotripsy (SWL), retrograde endoscopic procedures, and percutaneous nephrolithotomy. SWL is a safe, effective, noninvasive, and well-established treatment modality, which is now the first-choice treatment for most upper urinary tract stones \[[@B2]\].

Becoming stone-free after SWL does not occur immediately; instead, the stones are pulverized during the procedure, then spontaneously passed through the urinary tract. Thus, the time course of stone clearance varies considerably. In most cases, fragmented particles of calculi pass uneventfully through the urinary tract after SWL, but fragments sometimes obstruct the ureter, causing post-SWL complications such as acute renal colic, hydronephrosis, acute kidney injury, or urinary tract infection \[[@B3]\]. Particularly for larger calculi, a number of stone fragments may become impacted in the ureter, forming an obstructing column of sand known as steinstrasse. According to the European Association of Urology Urolithiasis Guidelines, ureteral stenting reduces the risk of renal colic and obstruction \[[@B4]\], and many physicians consider inserting ureteral stents before SWL to create an artificial chamber with an improved stone-fluid interface for better fragmentation during SWL and to reduce the risk of obstruction \[[@B5]\]. Accordingly, several studies have been performed to determine whether routine pre-SWL ureteral stenting is helpful in preventing obstructive complications, but the issue remains somewhat controversial \[[@B6][@B7][@B8]\].

Preventing post-SWL complication is surely important, but the ultimate goal of SWL treatment is to establish a stone-free status. Similar to the issue of ureteral stenting and SWL complications, the effects of SWL on stone-free rates (SFRs) are also controversial \[[@B7][@B9][@B10]\]. Several recent studies have demonstrated that ureteral stenting reduces the SFR following SWL \[[@B11][@B12][@B13]\], but the significance of this finding is debated. Thus, the current study was conducted to evaluate the effects of ureteral stenting and stone characteristics on ureteral stone clearance and to estimate the probability of one-session success in SWL patients with ureteral calculi according to whether they underwent ureteral stenting or exhibited various other factors.

MATERIALS AND METHODS
=====================

1. Patient cohort
-----------------

Medical records were obtained from a database of patients (n=1,651) who underwent an initial session of SWL between November 2005 and September 2014 at Severance Hospital, Seoul, Korea. The study inclusion criteria were a single, 4--20 mm, radiopaque calculus located within the ureter on plain-film X-rays, presenting within 1 month prior to SWL treatment, and without evidence of stone migration. Patients with bilateral ureteral stones, urinary tract congenital anomalies, or a single kidney, as well as those who received prophylactic medical expulsion therapy, were excluded from the analysis. This left 680 patients eligible for analysis.

2. Good clinical practice protocols
-----------------------------------

The study was performed in accordance with all applicable laws and regulations, good clinical practices, and the ethical principles described in the Declaration of Helsinki. The Institutional Review Board of Severance Hospital approved this study protocol (approval number: 4-2015-1052). The study was exempt from requiring the participants\' written informed consent because of its retrospective design and because the patients\' records and information were anonymized and de-identified prior to analysis.

3. Extracorporeal SWL
---------------------

SWL was performed using an electroconductive lithotripter (EDAP Sonolith Praktis, Technomed, Lyon, France) until 2011. Beginning in 2012, this was replaced by an electromagnetic generative lithotriptor (Dornier Compact Delta II lithotripter, Dornier Medtech, Wessling, Germany). All ESL procedures were conducted under fluoroscopic guidance. The number of shock waves per SWL session varied from 2,500 to 4,000, at a rate of 60--90 shock waves per minute. We prematurely terminated the session if the stone became difficult to visualize during the session. The launch intensity was conducted when the focal peak pressure ranged from 16 to 55 MPa, as determined by the pain reported by the patients while SWL was being performed.

4. Demographic data and stone characteristics on noncontrast computed tomography
--------------------------------------------------------------------------------

A detailed history of the ureteral stone was obtained, including the number of past stone events, history of pain onset, and stone characteristics. The stone characteristics included the location, maximal stone length (MSL), stone heterogeneity index (SHI), skin-to-stone distance (SSD), and mean stone density (MSD). The SSD was measured in the axial plane, 45° from the vertical axis \[[@B14]\]. The MSL was the longest stone length measured in three dimensions on noncontrast computed tomography (NCCT) images. We used the GE Centricity system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) during the measurement procedure. The MSD was measured using bone windows on the magnified, axial NCCT image of the stone in the maximal diameter, in which the elliptical region of interest incorporated the largest cross-sectional area of the stone without including adjacent soft tissue \[[@B15]\]. The SHI was defined as the standard deviation of the Hounsfield units (HUs) in the same region of interest by Lee et al. \[[@B16]\]. Complication rate and each variables including post-SWL complication were also obtained. Successful SWL treatment of the ureteric calculus was defined as the patient being rendered stone-free or asymptomatic with clinically insignificant residual fragments ≤3 mm in maximal diameter 2 weeks after a single SWL treatment (as measured by simple X-ray) \[[@B2]\] and not requiring additional treatment within a 3-month follow-up period.

5. Statistical analysis
-----------------------

Data are presented as mean±standard deviation. After total cohort analyses, propensity score matching was performed to further elucidate the characteristics of our patients with ureteral stones. Stenting cases were 1:6 matched with the closest-propensity stentless cases. Propensity scores were then calculated using a multivariable logistic regression model with a binomial method based on age and MSL (2 factors that demonstrated significant differences between the stenting and stentless groups in the total cohort) \[[@B17]\]. Propensity score matching can improve matching of patients, thereby forming a better comparator group. It is a balancing score, wherein the conditional distribution of the pretreatment characteristics given the propensity score is the same for the case and control groups \[[@B18]\]. The propensity score is most commonly estimated via an observational study involving patient and other background characteristics and using a multivariate logistic regression model.

Statistical comparisons of patient demographic continuous variables were performed using either a Student or Welch\'s two-sample t-test. Categorical variables were compared using Pearson chi-square test with Yates\' continuity correction. Univariate and multivariate logistic regression analysis using a binomial method were performed to identify factors significantly associated with one-session success. Optimal cutoff values for symptom severity were identified from the receiver operator characteristic (ROC) curves using Youden methods. Statistical analyses were performed using R software (ver. 3.0.3, R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org>) and its OptimalCutpoints package for optimal cutoff value.

RESULTS
=======

[Table 1](#T1){ref-type="table"} lists the baseline characteristics of the 680 patients who underwent primary SWL for a single ureteral calculus. The overall incidence of stenting during SWL for ureteral calculi was 8.3% (n=57). Comparisons between the stenting group and stentless groups based on patient and stone NCCT characteristics demonstrated that patient age and stone MSL were significantly different between the 2 groups. Stenting patients had a significantly longer MSL (12.03±6.02 mm in the stenting group, 8.96±3.57 mm in the stentless group, p\<0.001). There were no significant differences between groups for SSD (105.90±24.84 cm in the stenting group, 110.00±18.58 cm in the stentless group, p=0.135), MSD (717.86±285.06 HU in the stenting group, 707.14±271.20 HU in the stentless group, p=0.776), and SHI (237.89±121.75 HU in the stenting group, 242.62±107.27 in the stentless group, p=0.753). The number of previous stone episodes, stone location, and stone laterality demonstrated no differences between groups. Complication rate and each variables including post-SWL complication did not show significant differences between 2 groups. One-session success was significantly lower in the stenting group: 28 cases (49.1%) in the stenting group and 448 cases (71.9%) in the stentless group (p\<0.001) ([Table 1](#T1){ref-type="table"}).

After stenting and stentless cases were 1:6 propensity-matched, the one-session success rate of the stentless group (224 cases, 78.6%) was higher than that of the stenting group (28 cases, 49.1%) (p=0.026) ([Table 2](#T2){ref-type="table"}).

The univariate logistic regression models revealed the following predictive factors of one-session success following SWL for ureteral stones: shorter MSL (odds ratio \[OR\], 0.832; 95% confidence interval \[CI\], 0.792--0.872; p\<0.001), lower MSD (OR, 0.997; 95% CI, 0.996--0.998; p\<0.001), higher SHI (OR, 1.003; 95% CI, 1.001--1.005; p\<0.001) and absence of a stent (OR, 0.377; 95% CI, 0.217--0.653; p\<0.001). Multivariate analyses also demonstrated that a shorter MSL, lower MSD, higher SHI, and stentless cases were independent predictors of one-session success after SWL for ureteral calculi ([Table 3](#T3){ref-type="table"}).

In stenting cases, one-session failed and success groups were divided for subgroup analyses. Between failed and success groups in stenting cases, MSL and MSD demonstrated the significant differences ([Table 4](#T4){ref-type="table"}). For one-session success rates, the area under the curve (AUC) of ROC curves was 0.689 (95% CI, 0.635--0.742) for MSL and 0.686 (95% CI, 0.632--0.740) for MSD. The cutoff values for MSL and MSD were 10.0 mm and 784 HU, respectively. As shown in [Table 5](#T5){ref-type="table"}, the number of patients with one-session success status was higher in the stentless group than in the stenting group for patients with an MSL \>10 mm (p=0.002) or an MSD ≤784 HU (p=0.001).

DISCUSSION
==========

Since the introduction of ureteroscopy, SWL, and percutaneous nephrolithotomy, researchers have expended much effort to determine the factors associated with high success and low complication rates in the treatment of urinary stone disease. For SWL, factors reported to influence success and complication rates include the stone size, composition, density, and location; total number and frequency of shock waves; operators\' experience; and type of lithotripter. Pre-SWL ureteral stenting has also been proposed as an important way to reduce complications following SWL.

A primary rationale for performing ureteral stenting is to prevent complications associated with ureteral obstruction as stone fragments pass down the ureter. Several previous studies investigated the efficacy of ureteral stent in preventing these complications. Mohayuddin et al. \[[@B19]\] reported that steinstrasse and fever were not affected by whether or not a ureteral stent was used, but ureteral colic was significantly lower in their ureteral stenting group. In a prospective randomized clinical trial, the ureteral stenting group exhibited lower rates of hospital readmission and Emergency Department visits, and 13% of the stentless group but only 2% of the stenting group had steinstrasse formation \[[@B10]\]. In a recent meta-analysis, the authors noted that the steinstrasse rate was significantly lower in the stenting group, whereas fever, urinary tract infection, pain, and auxiliary treatment did not differ between groups \[[@B7]\]. From these results about post-SWL complications, the effects of ureteral stent for passage of fragments during SWL seem to be controversial.

Until now, reducing complications following SWL has been one of the most important goals of SWL for urinary stone management, although achieving stone-free status is the ultimate objective. Unfortunately, few reports have indicated that ureteral stents increase stone-free status or success rates following SWL. Several previous studies demonstrated that ureteral stents do not improve SWL success or SFR \[[@B9][@B10][@B19][@B20][@B21]\]. Rather, recent studies found that ureteral stents negatively affect SWL success or SFR. For example, Pettenati et al. \[[@B12]\] demonstrated that the presence of a ureteral stent negatively affects the efficacy of SWL in treating lumbar ureteral stones These authors found that the success rate with stenting was significant lower than the rate without stenting in patients with stones larger than 8 mm. Ozkan et al. \[[@B13]\] also reported that SFR was significantly higher in their stentless group than in their stenting group. Furthermore, in 2 randomized controlled trials, ureteral stenting was found to reduce the SFR \[[@B11]\], and the absence of an indwelling ureteral stent was an independent predictor of success \[[@B22]\].

Our results were similar to those of previous studies, supporting the negative effects of ureteral stenting on SFR. Although MSL, which can affect SFR, differed significantly between the stenting and stentless groups in our total cohort, the presence of a ureteral stent was the only factor that differed significantly between groups after 1:6 propensity score matching. The negative effects of stenting may be explained by 2 theories, which are not mutually exclusive. First, in order to have a maximal effect, shock waves must impinge on a stone surrounded by liquid. The ureteral stent may absorb some of the energy created by the shock waves, thus reducing their effect on the stones \[[@B9]\]. Second, the presence of a ureteral stent may cause ureteral edema, thus interrupting the passage of stone fragments \[[@B23][@B24][@B25]\]. The impact would be greater with ureteral stones than renal stones because the area of contact between the stone and stent would be larger and ureteral edema would have a greater effect on ureteral stones. Very few studies have distinguished between renal stones and ureteral stones.

Based on our findings and results of previous studies, pre-SWL ureteral stenting does not appear to have definite advantages in terms of SFR or complications, compared to in situ SWL. In addition, the decision to proceed with ureteral stenting requires much caution because it is a relatively invasive procedure. Furthermore, we should also consider the possibility of stent-related voiding symptoms, such as bladder irritation symptoms and flank pain or discomfort \[[@B26][@B27]\]. In their randomized control study, Ghoneim et al. \[[@B9]\] noted that microscopic hematuria, pyuria, dysuria, and suprapubic pain were significantly more common in patients with a ureteral stent than in those without. Another study, by El-Assmy et al. \[[@B20]\], of patients with ureteral stones 2 cm or less causing moderate or severe obstruction also showed that the rates of post-SWL morbidities related to ureteral stents (such as suprapubic pain, gross or microscopic hematuria, pyuria, and positive urine cultures) were significantly higher in their ureteral stenting group. Thus, we recommend against routine pre-SWL ureteral stenting; instead, ureteral stents should be reserved for special indications, such as complicated urinary tract infection or severe pain.

A unique aspect of our study is that we calculated the AUC and cutoff values for MSL and MSD, and then analyzed the SWL success rates according to the presence of a stent in subgroups based on these cutoff values. Since NCCT was introduced in the management of urinary tract stone disease, MSL and MSD have been widely recognized as predictors of SWL success rate \[[@B15][@B28][@B29][@B30]\]. In our multivariate logistic regression analysis, a shorter MSL, lower MSD, and absence of a stent were positive predictors for one-session success in patients who underwent SWL, which is consistent with the results of previous studies. The AUCs for MSL and MSD were high (0.689 and 0.686, respectively), compared to the AUCs for other factors. The cutoff values for MSL and MSD were 10.0 mm and 784 HU, respectively. When we analyzed the success rate of subgroups based on these cutoff values, the results for MSL were interestingly contrary to those observed for MSD. In patients with an MSL\>10 mm, the success rate was significantly lower in the stenting group, but in those with an MSL≤10 mm, there was no difference in success rate between the 2 groups. These findings are similar to those of Pettenati et al. \[[@B12]\], in which SWL success was lower in the stenting group only with larger stones, defined as a size \>8 mm. The differential effects of MSL may be explained to some degree by the theories mentioned above. Larger stones have a wider area of contact between the stone and stent, which presumably leads to greater energy absorption by the stent, thus increasing the likelihood of impaired stone fragmentation. By contrast, the success rate was higher in the stentless group than in the stent group in patients with a lower MSD (≤784 HU), representing a more fragile stone. If a stone is fragile, the stent can play a more significant role as an interference factor, thus promoting treatment failure.

Our results thus suggest that when physicians are deciding whether to perform ureteral stent insertion before SWL, they may consider MSL and MSD as factors influencing SWL failure (although further study is required to more definitively address this issue). In patients with a ureteral stone with a low MSD and large size, the decision to perform pre-SWL stenting should be based on symptoms and renal function of the patient. In addition, when physicians are trying to choose between treatment options, including retrograde ureteroscopic surgery and SWL, our overall higher one-session success rates with stones exhibiting a lower MSD and lower MSL (including both the stenting and stentless groups) suggest that it may be more appropriate to perform surgery in patients with stones with a high MSD and large volume.

This study has some inherent limitations because of its retrospective design, which may have introduced sampling bias; however, we used a relatively large cohort of patients undergoing SWL for ureteric stones. In addition, to overcome this type of limitation and elucidate the impact of MSL and MSD on SWL outcomes more clearly, we limited the study to include subjects who had only ureteric stones. With renal stones, anatomical considerations including the location of calyx and renal pelvic stones or the infundibulopelvic angle can be another source of bias. Furthermore, we could not analyze the reasons for stenting due to retrospective design. This may work as a significant bias because renal function or hydronephrosis grade which acts main causes of prestenting can be impact factors of SWL success rate. The 2 different lithotripsy machines may be a source of bias, but there were no statistical differences between the 2 time periods (data not shown). Despite these limitations, the study has certain strengths, including our focus on the results of SFR as a more important goal than complication rates and our analysis of one-session success rates following SWL according to stone characteristics (MSL and MSD) in relation to the presence of a stent. In the future, large prospective studies are needed to confirm our observations on the negative effect of ureteral stenting on SFR.

CONCLUSIONS
===========

Ureteral stenting during SWL was a negative predictive factor for one-session success in patients with a single ureteral stone. Furthermore, in patients with stones that exhibited a lower MSD and higher MSL, ureteral stenting negatively influenced one-session outcomes, compared to SWL without stenting.
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###### Demographic data and success rate comparisons between stenting and stentless groups for the total cohort

![](icu-57-408-i001)

  Variable               Total cohort (n=680)   Stenting group (n=57)   Stentless group (n=623)   p-value
  ---------------------- ---------------------- ----------------------- ------------------------- ------------
  Age (y)                52.18±14.33            56.86±14.10             51.75±14.29               0.010^a^
  Sex                                                                                             0.873^b^
   Male                  442 (65.0)             36 (63.2)               406 (65.2)                
   Female                238 (35.0)             21 (36.8)               217 (34.8)                
  MSL (mm)               9.22±3.92              12.03±6.02              8.96±3.57                 \<0.001^a^
  SSD (cm)               110.50±19.22           105.90±24.84            110.00±18.58              0.135^a^
  MSD (HU)               708.04±272.19          717.86±285.06           707.14±271.20             0.776^a^
  SHI (HU)               242.22±108.47          237.89±121.75           242.62±107.27             0.753^a^
  Prior stone episodes                                                                            0.763^b^
   FSF                   483 (71.0)             39 (68.4)               444 (71.3)                
   RSF                   197 (29.0)             18 (31.6)               179 (28.7)                
  Stone location                                                                                  0.482^b^
   Upper                 554 (81.5)             46 (80.7)               508 (81.5)                
   Middle                48 (7.0)               6 (10.5)                42 (6.7)                  
   Lower                 78 (11.5)              5 (8.8)                 73 (11.7)                 
  Stone laterality                                                                                0.610^b^
   Right                 324 (47.6)             29 (50.9)               295 (47.4)                
   Left                  356 (52.4)             28 (49.1)               328 (52.6)                
  Complication rate      25 (3.7)               23 (3.7)                2 (3.5)                   1.000
   Pyelonephritis        1 (0.1)                1 (0.2)                 0 (0.0)                   
   Hematuria             2 (0.3)                2 (0.3)                 0 (0.0)                   
   Colic pain            21 (3.1)               19 (3.0)                2 (3.5)                   
   GI symptoms           1 (0.1)                1 (0.2)                 0 (0.0)                   
  One-session success    476 (70.0)             28 (49.1)               448 (71.9)                \<0.001^b^

Values are presented as mean±standard deviation or number (%).

MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; FSF, first-time stone formers; RSF, recurrent stone formers; HU, Hounsfield units.

^a^:Based on Student or Welch\'s two-sample t-tests. ^b^:Based on Pearson chi-square tests with Yates\' continuity correction.

###### Demographic data and success rate comparisons between stenting and stentless groups for the propensity-matched cohort

![](icu-57-408-i002)

  Variable               Total matched cohort (n=399)   Stenting group (n=57)   Stentless group (n=342)   p-value
  ---------------------- ------------------------------ ----------------------- ------------------------- ----------
  Age (y)                56.22±13.86                    56.86±14.10             56.11±13.84               0.708^a^
  Sex                                                                                                     0.681^b^
   Male                  265 (66.4)                     36 (63.2)               229 (67.0)                
   Female                134 (33.6)                     21 (36.8)               113 (33.0)                
  MSL (mm)               10.75±4.27                     12.03±6.02              10.53±3.88                0.075^a^
  SSD (cm)               110.30±20.25                   105.90±24.84            111.50±19.46              0.140^a^
  MSD (HU)               758.14±285.11                  717.86±285.06           764.94±284.92             0.250^a^
  SHI (HU)               250.43±116.45                  237.89±121.75           250.99±117.80             0.381^a^
  Prior stone episodes                                                                                    0.763^b^
   FSF                   280 (70.2)                     39 (68.4)               241 (70.5)                
  RSF                    119 (29.8)                     18 (31.6)               101 (29.5)                
  Stone location                                                                                          0.617^b^
   Upper                 328 (82.2)                     46 (80.7)               282 (82.5)                
   Middle                30 (7.5)                       6 (10.5)                24 (7.0)                  
   Lower                 41 (10.3)                      5 (8.8)                 36 (10.5)                 
  Stone laterality                                                                                        0.775^b^
   Right                 196 (49.1)                     29 (50.9)               167 (48.8)                
   Left                  203 (50.8)                     28 (49.1)               175 (51.2)                
  One-session success    252 (63.1)                     28 (49.1)               224 (78.6)                0.026^b^

Values are presented as mean±standard deviation or number (%).

MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; FSF, first-time stone formers; RSF, recurrent stone formers; HU, Hounsfield units.

^a^:Based on Student or Welch\'s two-sample t-tests. ^b^:Based on Pearson chi-square tests with Yates\' continuity correction.

###### Univariate and multivariate logistic regression models for predictive factors of one-session success following shock wave lithotripsy for ureteral stones
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  Parameter                  Odds ratio   95% CI         p-value
  -------------------------- ------------ -------------- ---------
  Univariate                                             
   Age                       1.006        0.995--1.018   0.275
   Male sex                  0.793        0.557--1.122   0.195
   MSL                       0.832        0.792--0.872   \<0.001
   MSD                       0.997        0.996--0.998   \<0.001
   SSD                       1.001        0.992--1.010   0.799
   SHI                       1.003        1.001--1.005   \<0.001
   Recurrent stone formers   1.152        0.802--1.670   0.452
   Stone location (%)                                    
    Upper                    Reference                   
    Middle                   0.683        0.373--1.281   0.222
    Lower                    0.868        0.527--1.466   0.588
   Laterality, right         1.204        0.866--1.674   0.269
   Stenting                  0.377        0.217--0.653   \<0.001
  Multivariate                                           
   MSL                       0.901        0.854--0.948   \<0.001
   MSD                       0.996        0.994--0.997   \<0.001
   SHI                       1.010        1.007--1.012   \<0.001
   Stenting                  0.432        0.217--0.863   0.017

CI, confidence interval; MSL, maximal stone length; MSD, mean stone density; SSD, skin-to-stone distance; SHI, stone heterogeneity index.

###### Demographic and factor comparisons between failed and success groups in stenting patients
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  Variable           Failed group (n=29)   Success group (n=28)   p-value
  ------------------ --------------------- ---------------------- ----------
  Age (y)            57.90±12.59           55.79±15.67            0.577^a^
  Sex                                                             1.000^b^
   Male              18 (62.1)             18 (64.3)              
   Female            11 (37.9)             10 (35.7)              
  MSL (mm)           13.54±6.25            10.46±5.45             0.052^a^
  SSD (cm)           108.39±26.24          103.24±23.49           0.438^a^
  MSD (HU)           809.56±326.92         622.89±198.31          0.012^a^
  SHI (HU)           225.28±121.47         250.96±122.85          0.431^a^
  Stone location                                                  0.202^b^
   Upper             25 (86.2)             21 (75.0)              
   Middle            1 (3.4)               5 (17.9)               
   Lower             3 (10.3)              2 (7.1)                
  Stone laterality                                                0.144^b^
   Right             12 (41.4)             17 (58.6)              
   Left              17 (58.6)             11 (39.3)              

Values are presented as mean±standard deviation or number (%).

MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; HU, Hounsfield units.

^a^:Based on Student or Welch\'s two-sample t-tests. ^b^:Based on Pearson chi-square tests with Yates\' continuity correction.

###### Comparison of stone-free status in stenting and stentless group according to optimal cutoff value for MSD and MSL
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  Variable               Stenting group   Stentless group   p-value^a^
  ---------------------- ---------------- ----------------- ------------
  MSD \> 784 HU                                             0.135
   Total                 21               205               
   One-session success   6 (28.6)         99 (48.3)         
  MSD ≤ 784 HU                                              0.001
   Total                 36               418               
   One-session success   22 (61.1)        349 (83.5)        
  MSL \> 10 mm                                              0.002
   Total                 28               178               
   One-session success   8 (28.6)         93 (52.2)         
  MSL ≤ 10 mm                                               0.294
   Total                 29               449               
   One-session success   20 (69.0)        355 (79.1)        

Values are presented as number or number (%).

MSD, mean stone density; MSL, maximal stone length; HU, Hounsfield units.

^a^:Pearson chi-square test with Yates\' continuity correction.
